227 related articles for article (PubMed ID: 21497649)
21. Recent advances in the treatment of APL.
Sanz MA
Clin Adv Hematol Oncol; 2006 Oct; 4(10):727-9. PubMed ID: 17099628
[No Abstract] [Full Text] [Related]
22. What is the role of arsenic in newly diagnosed APL?
Tallman MS
Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
[TBL] [Abstract][Full Text] [Related]
23. Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor.
Monzen H; Griffin RJ; Williams BW; Amano M; Ando S; Hasegawa T
Radiat Med; 2004; 22(4):205-11. PubMed ID: 15468939
[TBL] [Abstract][Full Text] [Related]
24. [Advances in the study on antineoplastic action of realgar].
Pan B; Xu L; Yang X
Zhong Yao Cai; 2004 Mar; 27(3):226-9. PubMed ID: 15346589
[No Abstract] [Full Text] [Related]
25. [Safety evaluation of realgar-and cinnabar-containing traditional Chinese medicine].
Lu Y; Shi J; Shi J; Liu J
Zhongguo Zhong Yao Za Zhi; 2011 Dec; 36(24):3402-5. PubMed ID: 22368844
[TBL] [Abstract][Full Text] [Related]
26. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
27. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
28. (1)H NMR-based metabonomics study on the toxicity alleviation effect of other traditional Chinese medicines in Niuhuang Jiedu tablet to realgar (As2S2).
Xu W; Wang H; Chen G; Li W; Xiang R; Pei Y
J Ethnopharmacol; 2013 Jun; 148(1):88-98. PubMed ID: 23583735
[TBL] [Abstract][Full Text] [Related]
29. Membrane-associated cytotoxicity induced by realgar in promyelocytic leukemia HL-60 cells.
Ye HQ; Gan L; Yang XL; Xu HB
J Ethnopharmacol; 2006 Feb; 103(3):366-71. PubMed ID: 16174554
[TBL] [Abstract][Full Text] [Related]
30. Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines.
Ramos AM; Aller P
Biochem Pharmacol; 2008 May; 75(10):1912-23. PubMed ID: 18359480
[TBL] [Abstract][Full Text] [Related]
31. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
Sanz MA; Fenaux P; Lo Coco F;
Haematologica; 2005 Sep; 90(9):1231-5. PubMed ID: 16154847
[TBL] [Abstract][Full Text] [Related]
32. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis.
Li Y; Zhu X; Gu J; Dong D; Yao J; Lin C; Huang K; Fei J
Cancer Sci; 2010 Apr; 101(4):948-54. PubMed ID: 20148895
[TBL] [Abstract][Full Text] [Related]
33. Realgar (As
Li Z; Zhang R; Yin X; Li N; Cui S; Wang T; Tan X; Shen M; Guo Y; Wang J; Guo D; Xu R
Aging (Albany NY); 2022 Sep; 14(17):7109-7125. PubMed ID: 36098742
[TBL] [Abstract][Full Text] [Related]
34. Dissection of scientific compatibility of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia from the perspective of toxicology.
Jiang Z; Sun Y; Wu Z; Tang M; Ye A; Tu B; Yi J; Xu H; Gao Y
J Ethnopharmacol; 2023 Dec; 317():116895. PubMed ID: 37467822
[TBL] [Abstract][Full Text] [Related]
35. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
Carmosino I; Latagliata R; Avvisati G; Breccia M; Finolezzi E; Lo Coco F; Petti MC
Haematologica; 2004 May; 89(5):615-7. PubMed ID: 15136230
[TBL] [Abstract][Full Text] [Related]
36. Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy.
Ebinger M; Schwarze CP; Feuchtinger T; Scheel-Walter HG; Lang P; Hildenbrand S; Gessler P; Handgretinger R
Pediatr Hematol Oncol; 2011 May; 28(4):334-7. PubMed ID: 21345080
[TBL] [Abstract][Full Text] [Related]
37. [Arsenic trioxide as a therapeutic agent in APL].
Emi N
Nihon Rinsho; 2007 Jan; 65 Suppl 1():724-8. PubMed ID: 17474483
[No Abstract] [Full Text] [Related]
38. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
39. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.
Mathews V; George B; Chendamarai E; Lakshmi KM; Desire S; Balasubramanian P; Viswabandya A; Thirugnanam R; Abraham A; Shaji RV; Srivastava A; Chandy M
J Clin Oncol; 2010 Aug; 28(24):3866-71. PubMed ID: 20644086
[TBL] [Abstract][Full Text] [Related]
40. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
